Warfarin sodium as an anticoagulant، is widely used for the prevention and treatment of venous and arterial thrombosis. As a vitamin K antagonist، warfarin effectively decreases the hepatic production of clotting factors II، VII، IX، and X، along with proteins C and S. While anticoagulants such as warfarin have well-established indications، they are also associated with few side effects such as haemorrhage. Many patients receiving vitamin K antagonists have an International Normalized Ratio (INR) higher than the target of 2. 0 to 3. 0 for over 50% of the time، which is followed with increasing risk of bleeding. In this situation the clinical need for emergency reversal of anticoagulation is necessary. There are a number of potential treatment options for anticoagulant reversal، including administration of vitamin K (oral or intravenous)، human plasma products [for example، Fresh Frozen Plasma (FFP)]، prothrombin complex concentrates (PCCs); concentrates that contain coagu-lation factors II، VII، IX and X)، or single coagulation factors such as activated re-combinant factor VII (rFVIIa). The aim of this paper was to conduct a review of the medical literature and summarize the advantages and risks of the available treatment options for reversing warfarin anticoagulation in patients receiving warfarin.